- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04479072
Aspirin and Preeclampsia
Aspirin to Prevent Cardiac Dysfunction in Preeclampsia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the main part of this trial is to mechanistically compare the effect of postpartum aspirin therapy versus placebo in preeclamptic patients identified as high risk for postpartum cardiac dysfunction using Activin A. The intent is to evaluate the effect of selective treatment based on Activin A status rather than treatment for all postpartum preeclamptic women.
After informed consent, 5cc of blood will be collected from the median cubital vein on antepartum admission to labor and delivery for Activin A screening. The patient will be subjected to a total of 2 such blood draws- a single draw at screening, one at their 6 month postpartum visit. The member of the study team carrying out the blood draw will immediately label the specimen in the presence of the subject, after the collection and before leaving the patient's bedside, room, cubicle or surgical suite. The guidelines from, "The University of Chicago Medicine Policy and Procedure Manual - Phlebotomy Service Infection Control 04-26" will be followed for specimen collection and transport. Activin A levels based on our previous data will be classified as elevated if greater than 23.74 ng/ml in the last trimester of pregnancy (4). This threshold was selected on the basis of our prior data suggesting an inflection point in the rate of abnormal GLS postpartum at this concentration. Patients with elevated Activin A levels will be randomized to a placebo group receiving routine postpartum cardiovascular standard of care or to an intervention arm with 81 mg daily aspirin therapy added to care at their postpartum delivery stay. The rationale for only randomizing women with elevated Activin A levels is that among women with an elevated Activin A antepartum, 85% developed abnormalities in GLS at one year postpartum versus 25% in women with non-elevated Activin A levels. Women whose Activin A levels are not elevated will receive the same care as that provided to the placebo group and will also be followed for one year (n=60). All other subjects who meet the criterial of elevated Activin A levels, will either be randomized to the aspirin therapy group (N = 60) or a placebo group (N = 60). The investigators choose postpartum Aspirin therapy post-delivery to avoid any immediate delivery or C-section associated bleeding complications and to coincide with their postpartum well-baby visit.
The investigator will determine the blood Activin A levels at 6 months after delivery, measured using ELISA. The samples will be assayed for Activin A level using commercially available ELISA kits (Ansh Labs; Webster, TX) following the manufacturer's recommendations. Each sample will be run in triplicate and the values averaged. GLS at 6 months after delivery will be measured using fully automated vendor-independent software that uses a computer learning algorithm to facilitate endocardial border detection.
Mean arterial pressure, and other indices of systolic and diastolic function (ejection fraction (EF), early filling/atrial contraction (E/A), deceleration time (DT), mitral annular motion (E'), and left atrial volume index) measured at the baseline and 6 months postpartum. Transthoracic echocardiograms will be performed and reported according to American Society of Echocardiography guidelines. Ejection fraction and left atrial volume will be calculated using the Simpson's biplane disc method. Left ventricular mass index (LVMI) will be calculated using the area length method.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sajid Shahul, MD, PhD
- Phone Number: 773-398-2956
- Email: sshahul1@dacc.uchicago.edu
Study Contact Backup
- Name: Colleen Duncan, RN
- Phone Number: 7738342892
- Email: cduncan@bsd.uchicago.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago Hospital
-
Contact:
- Sajid Shahul, MD, PhD
- Phone Number: 773-398-2956
- Email: sshahul1@dacc.uchicago.edu
-
Contact:
- John Dreixler, PhD
- Phone Number: 773-702-6700
- Email: JDreixle@dacc.uchicago.edu
-
Sub-Investigator:
- Sarosh Rana, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant Adults between 18 and 45 years of age
- Diagnosed with preeclampsia
- Presenting for delivery with a singleton gestation.
Exclusion Criteria:
- We will exclude patients in labor
- Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
- Plan to deliver outside of the participating site
- Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
- Aspirin allergy
- Clear indication for aspirin therapy or contraindication to aspirin therapy
- Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
- Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
- Those who cannot provide consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention Arm
60 subjects will be randomly assigned to this arm.
The subjects in this arm will receive a daily dose of aspirin 81 mg.
|
Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Other Names:
|
Placebo Comparator: Placebo Arm
60 subjects will be randomly assigned to this arm.
The subjects in this arm will receive a daily dose of a placebo pill
|
Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
|
No Intervention: Observational Arm
60 subjects will be placed in the observational arm.
These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in Activin A levels
Time Frame: 6 Months
|
The primary outcome will compare Activin A levels at 6 months between patients randomized to aspirin therapy versus placebo and the observational group.
|
6 Months
|
GLS percentages
Time Frame: 6 months
|
The primary outcome will compare GLS levels as a percentage (%) at 6 months between patients randomized to aspirin therapy versus placebo and the observational group.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Arterial Pressure
Time Frame: 6 Months
|
Difference in mean arterial pressure in subjects, from their baseline to 6 month TTE
|
6 Months
|
Ejection Fraction %
Time Frame: 6 Months
|
Comparing the difference in the ejection fraction percentages, from the subjects baseline to 6 month TEE.
|
6 Months
|
Deceleration Time
Time Frame: 6 Months
|
Comparing the difference between deceleration time from subjects from their baseline to 6 month TTE.
|
6 Months
|
Mitral Annular Motion
Time Frame: 6 Months
|
Comparing the difference between mitral annular motion, in millimeters (mm), from subjects baseline to 6 month TTE.
|
6 Months
|
Left Atrial Volume Index
Time Frame: 6 Months
|
Comparing the difference between left atrial volume index, from the subjects baseline to 6 month TTE.
|
6 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pregnancy Complications
- Hypertension, Pregnancy-Induced
- Pre-Eclampsia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- IRB18-1606
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preeclampsia Postpartum
-
Brigham and Women's HospitalCompletedHypertension in Pregnancy | Postpartum | Postpartum Preeclampsia | Gestational Hypertension | Preeclampsia SevereUnited States
-
University Medical Centre LjubljanaCompletedPreeclampsia Postpartum | Preeclampsia SevereSlovenia
-
Columbia UniversityCompletedHypertension | Hypertension, Pregnancy-Induced | Postpartum Preeclampsia | Postpartum Pregnancy-Induced HypertensionUnited States
-
Yale UniversityRecruitingPostpartum Depression | Postpartum Hemorrhage | Patient Empowerment | Patient Education | Postpartum Sepsis | Postpartum Preeclampsia | Postpartum CareUnited States
-
MemorialCare Health SystemNot yet recruitingPreeclampsia | Preeclampsia Postpartum | Preeclampsia Severe | Preeclampsia Mild
-
Hospital de la MujerOcharan-Hernández, Esther, MD, PhD; Vargas-De-León, Cruz, MSc; Calzada-Mendoza...Completed
-
Columbia UniversityRecruiting
-
University of ChicagoRecruiting
-
Washington University School of MedicineRecruitingPreeclampsia Postpartum | Preeclampsia SevereUnited States
-
Weill Medical College of Cornell UniversityNot yet recruitingPostpartum Depression | Postpartum Hemorrhage | Patient Empowerment | Patient Education | Postpartum Sepsis | Postpartum Preeclampsia | Postpartum CareUnited States
Clinical Trials on Aspirin 81 mg
-
PhytoHealth CorporationActive, not recruitingSurvival | Cancer-related Fatigue | Tumor, EsophagealTaiwan
-
University of TennesseeWithdrawn
-
Sudeep ShivakumarCanadian Institutes of Health Research (CIHR); Nova Scotia Health Authority; Canadian...Recruiting
-
The University of Texas Health Science Center,...Active, not recruitingObesity | Pre-Eclampsia | Hypertension in PregnancyUnited States
-
Aswan University HospitalUnknown
-
University of UtahCompletedMelanoma (Skin)United States
-
Ottawa Heart Institute Research CorporationSuspendedMyocardial Infarction | Coronary Artery DiseaseCanada
-
Janssen Research & Development, LLCCompleted